Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
OATP-F CRISPR/Cas9 KO Plasmid (h): sc-405736
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- OATP-F CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the OATP-F genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: OATP-F Antibody (G-5): sc-398883
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
OATP-F CRISPR/Cas9 KO Plasmid (h) | sc-405736 | 20 µg | $397.00 |
Overview
SLCO1C1 encodes the human organic anion transporting polypeptide OATP-F (OATP1C1), a plasma membrane solute carrier that mediates sodium-independent uptake of thyroid hormones and related iodothyronines, with high affinity for thyroxine (T4) and reverse triiodothyronine (rT3). This transporter is prominently implicated in controlling hormone availability at tissue barriers, including the blood–brain barrier, thereby influencing local thyroid hormone homeostasis and downstream transcriptional programs regulated by thyroid hormone receptors. By shaping intracellular iodothyronine flux, OATP-F intersects with endocrine signaling, metabolic regulation, and xenobiotic handling pathways that depend on controlled transporter-mediated substrate access. Altered transporter activity or expression is relevant to research on neuroendocrine regulation and disorders linked to disrupted thyroid hormone distribution and signaling.
OATP-F CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the SLCO1C1 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the SLCO1C1 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the SLCO1C1 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish OATP-F protein expression.
This CRISPR knockout system enables efficient generation of SLCO1C1-deficient cell models for investigation of OATP-F signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting SLCO1C1 exon(s) critical for OATP-F function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple SLCO1C1 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by OATP-F CRISPR/Cas9 KO Plasmid (h) and OATP-F CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the SLCO1C1 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by OATP-F HDR Plasmid (h) and OATP-F HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by SLCO1C1 homology arms to support homology-directed repair at defined SLCO1C1 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.